GlassScriptPhysician profile
Khusbu Patel
NPI 1962107953
$4,153.78
in general payments reported to CMS, 2019-2025
33 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 92% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,131 · 2024: $1,351 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $687.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $608.36 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $449.16 | 2024-2025 | Tepezza, Repatha, Prolia |
| Insulet Corporation | $266.52 | 2023-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $209.87 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $188.58 | 2023-2025 | Tymlos |
| Sequel Med Tech, LLC | $182.84 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $156.92 | 2023-2025 | |
| Corcept Therapeutics | $155.16 | 2023-2025 | Korlym |
| Dexcom, INC. | $120.49 | 2023 | Dexcom G7 Gss (161) |
| Ascendis Pharma Endocrinology INC | $109.05 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $99.29 | 2023-2025 | Strensiq |
| Abbvie INC. | $97.18 | 2023-2025 | |
| Mannkind Corporation | $85.04 | 2025 | |
| Ascensia Diabetes Care US INC. | $83.67 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $83.40 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $79.57 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $72.22 | 2023-2024 | Unithroid |
| Embecta Corp. | $57.24 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Recordati_rare_diseases_inc. | $47.54 | 2024 | Isturisa, Signifor Lar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.14 | 2023-2024 | Cycloset |
| Madrigal Pharmaceuticals | $40.52 | 2025 | Rezdiffra |
| Amphastar Pharmaceuticals, INC. | $34.10 | 2024-2025 | |
| Astellas Pharma US INC | $33.08 | 2025 | Veozah |
| Amryt Pharma Holdings LTD | $26.59 | 2023 | Myalept, Mycapssa |
| Azurity Pharmaceuticals, INC. | $21.48 | 2023 | Adthyza |
| Verity Pharmaceuticals INC. | $21.38 | 2024 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.76 | 2024 | Jardiance, Synjardy |
| Nevro Corp. | $15.46 | 2023 | Senza |
| Silk Road Medical, INC. | $14.47 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Ionis Pharmaceuticals, INC. | $14.45 | 2025 | Tryngolza |
| Vivus LLC | $14.07 | 2023 | Qsymia |
| Acella Pharmaceuticals, LLC | $13.46 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khusbu Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.